Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

NCT06567600 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma
Chemotherapy Effect
Immunotherapy

Interventions

DRUG: Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Collaborators

[object Object]